JNJ Intrinsic Value Calculator – Johnson & Johnson Wins Approval for Prostate Cancer Therapy in Canada

☀️Trending News

Johnson & Johnson ($NYSE:JNJ), a healthcare giant and one of the largest pharmaceutical companies in the world, has just won approval from the Canadian government for its prostate cancer therapy. This conditional approval marks an important milestone for the company as it expands its reach to Canada. Johnson & Johnson is a multinational corporation that manufactures and markets a wide variety of consumer products, pharmaceuticals, and medical devices. The company’s success can be credited to its diversified range of products and services, as well as its commitment to research and development. The company’s newly approved prostate cancer therapy is part of its larger portfolio of oncology treatments.

This therapy has been shown to be more effective than existing treatments. While the therapy is still in clinical trials, it has already shown promising results in terms of reducing tumor size and improving survival rates. The approval of the prostate cancer therapy marks another step forward for Johnson & Johnson’s oncology portfolio and further demonstrates their commitment to developing innovative treatments. The company is continuing to invest in research and development to better serve their customers and provide better treatments for patients.

Price History

On Wednesday, Johnson & Johnson stock opened at $161.6 and closed at $161.6, up by 0.5% from its prior closing price of 160.7 after the company announced that it had won approval from Health Canada for its prostate cancer therapy, erdafitinib. This approval is a major milestone for Johnson & Johnson as it marks the first ever approval of a therapy specifically designed to treat advanced prostate cancer. With Health Canada approval now secured, Johnson & Johnson is one step closer to making this therapy available to Canadian men suffering from advanced prostate cancer.

This news was seen as positive by investors, with the stock price rising slightly after the announcement. As Johnson & Johnson continues to work towards bringing this therapy to market, investors will continue to watch the stock closely, hoping for more positive news in the future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for JNJ. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for JNJ. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for JNJ. More…

Key Ratios Snapshot

Some of the financial key ratios for JNJ are shown below. More…

Analysis – JNJ Intrinsic Value Calculator

At GoodWhale, we have carefully analyzed the financials of JOHNSON & JOHNSON to calculate an intrinsic value for their shares. According to our proprietary Valuation Line, the intrinsic value of JOHNSON & JOHNSON share is around $177.4. Currently, the stock of JOHNSON & JOHNSON is traded at $161.6, indicating that it is undervalued by 8.9%. This presents an excellent opportunity to invest in JOHNSON & JOHNSON stock at a fair price. More…

Peers

The competition between Johnson & Johnson and its competitors is fierce. AstraZeneca PLC, Pfizer Inc, and BioNTech SE are all major players in the pharmaceutical industry, and they are all vying for a piece of the pie. Johnson & Johnson is a well-established company with a long history of success, but its competitors are not to be underestimated. They are all large, well-funded companies with a lot to lose if they don’t win the competition.

– AstraZeneca PLC ($LSE:AZN)

AstraZeneca PLC is a biopharmaceutical company with a market cap of 152.13B as of 2022. The company focuses on the discovery, development, and commercialization of small molecule drugs in the areas of oncology, cardiovascular, and renal & metabolism. The company’s ROE for the year ended December 31, 2020 was -0.94%.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a pharmaceutical company with a market cap of 240.55B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The company’s products include prescription and over-the-counter medicines, vaccines, and biologic therapies.

– BioNTech SE ($NASDAQ:BNTX)

BioNTech SE is a German biotech company founded in 2008 that focuses on the development of Innovation therapies against cancer and other serious diseases. The company has a market cap of 32.91B as of 2022 and a Return on Equity of 71.82%. BioNTech’s mission is to revolutionize the treatment of cancer and other serious diseases by leveraging the power of the immune system. The company is developing a portfolio of immunotherapy products based on its proprietary mRNA technology platform.

Summary

Johnson & Johnson has been granted conditional approval in Canada for its prostate cancer therapy, Erleada. The drug is the first oral therapy of its kind to target non-metastatic castration-resistant prostate cancer (nmCRPC). The approval is seen as a positive development for J&J and could provide a boost to the company’s stock price. Investors should watch for potential revenue growth as the drug is expected to be covered by public and private healthcare providers.

Additionally, Erleada could be used to prolong the lives of men with non-metastatic prostate cancer, potentially leading to increased investor confidence in J&J. It is important to note that long-term success of Erleada could be affected by potential competition from other therapies and drugs.